SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Emile Griffith — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientEmile Griffith
Date of birth1938-02-03
IdentifiersMRN HR-BX005-SYN-TD; SSN (made up) 000-05-6418
Document date2005-06-16
AuthorCeleste Fairbanks-Ochieng, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-week review: neuropsychological testing results and the diagnosis. [S]

History of Present Illness

Emile Griffith returns with his care partner for the results of his neuropsychological testing, done a week ago, and of the work-up. He has had three sessions of cognitive processing therapy; he says it is hard to write about the fight but he feels lighter after each session, and the psychologist gives him one-page summaries that his care partner reads with him between sessions. Nightmares come four or five nights a week instead of most nights. He takes sertraline 25 mg each morning without side effects. He has had no falls and no thoughts of suicide. His care partner says he repeats stories less when he is rested. He asked to hear the results with his care partner present. [S]

ElementDetail
Neuropsychological testingMild cognitive impairment of frontal-subcortical type; retrieval better with cues; effort valid
PCL-537, from 41 at intake
PHQ-98; item 9 scored 0
TherapyThree sessions of cognitive processing therapy
Physical therapyEvaluation booked for next week

Review of Systems

SystemResultFinding
NeurologicalPositiveForgetfulness, better when rested; no headaches, weakness or tremor
PsychiatricPositiveNightmares four or five nights a week; less guilt; mood better; no thoughts of suicide
GastrointestinalNegativeNo nausea or diarrhea
MusculoskeletalNegativeNo falls

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sertraline 25 mg oral tablet, one tablet each morningOne tablet each morningOral route2005-05-05 to 2005-06-16completedS
Sertraline 50 mg oral tablet, one tablet each morningOne tablet each morningOral route2005-06-16activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2005-06-16Body height170cmS
2005-06-16Body weight73.6kgS
2005-06-16Body mass index (BMI) [Ratio]25.5kg/m2S
2005-06-16Systolic blood pressure128mm[Hg]S
2005-06-16Diastolic blood pressure78mm[Hg]S
2005-06-16Heart rate68/minS
2005-06-16Respiratory rate14/minS
2005-06-16Body temperature36.6CelS
2005-06-16Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2005-06-16Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]8{score}S
2005-06-16PTSD PCL-5 score [PCL-5]37{score}S

Physical Exam

Vital signs recorded on 2005-06-16; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 128/78 mmHg; pulse 68; weight 73.6 kg
NeurologicalUnchanged: no rigidity, tremor or slowness; slightly wide-based gait
Mental statusAlert and engaged; asks good questions about the results and repeats the main points back correctly; no psychotic symptoms; denies thoughts of suicide

Problems

ProblemClinical statusVerificationCodeProvenance
Memory loss and confusion over about a year, worse in recent months, reported by him and his care partner: repeating stories and questions, losing the thread of conversations, mixing up days, two missed appointments, and once getting lost changing trains on a familiar route; cause to be foundresolvedconfirmed R41.3S — Synthetic presenting problem anchored to the documented short-term memory problems; resolved into the diagnosis at the third visit. Not a claim about his real symptoms at that age.
Post-traumatic stress disorder, chronic, after two index events (a title fight decades ago after which his opponent died, and a severe assault thirteen years ago): nightmares, unwanted images, avoidance of fight footage, guilt and self-blame, being on guard in crowds, poor sleep; PCL-5 41activeconfirmed F43.12S — Synthetic modern diagnosis at intake by clinical interview against DSM-5-TR criteria, anchored to his public words about lifelong nightmares; not a historical diagnosis.
Mild cognitive impairment (mild neurocognitive disorder) with slowed processing, executive and memory-retrieval deficits, most likely due to traumatic brain injury from a nineteen-year professional boxing career and a severe assault; meets the NINDS research criteria for traumatic encephalopathy syndrome (a research diagnosis); Alzheimer's disease co-pathology not excludedactiveconfirmed G31.84S — Synthetic modern diagnosis at the third visit after MRI and neuropsychological testing; anchored to the documented memory problems and pugilistic dementia, not a retrospective diagnosis of his real illness.
Personal history of traumatic brain injury: repetitive head impacts over 112 professional bouts, and a severe head injury in an assault thirteen years ago with months in hospitalactiveconfirmed Z87.820S — Synthetic coding of the documented career and assault.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyCognitive testing (MoCA)At diagnosis, then yearly, or sooner with changeUp to dateMoCA 22 at intake; next in about a year
SurveyStaging (CDR) and function (ADL and IADL)At diagnosis, then yearlyUp to dateGlobal CDR 0.5 at two weeks; function unchanged
LaboratoryReversible causes: blood count, metabolic panel, B12, TSH, depression, sleep apnea, hearing and visionOnce at diagnosisUp to dateCompleted at intake and two weeks; no reversible cause found beyond PTSD, depressive symptoms and poor sleep, which are being treated
ImagingStructural brain MRIOnce at diagnosis; repeat only with an atypical course or focal changeUp to dateDone at two weeks; no repeat needed
SurveyNeuropsychological testingAt diagnosis when the cause or stage is unclear; repeat in 12 to 18 months or with changeCompleted todayTesting a week ago reviewed today: slowed processing, reduced set-shifting and fluency, retrieval better with cues; mild cognitive impairment of frontal-subcortical type
LaboratoryAlzheimer's disease biomarkers (blood, CSF or amyloid PET)When the result would change diagnosis or managementNot indicatedExplained and declined for now; would not change his care, and seven microbleeds would exclude anti-amyloid antibodies
ExaminationMedicine review for anticholinergic, sedating and fall-risk drugs (Beers)Every visitCompleted todaySertraline only; no cholinesterase inhibitor started (no benefit shown in mild cognitive impairment)
SurveyNeuropsychiatric symptom screen (apathy, irritability, paranoia, impulsivity)Every visitCompleted todayNo apathy, irritability, paranoia or impulsive behavior
SurveyPHQ-9 with suicide-risk review (item 9 and structured questions)Monthly during acute treatment; every visit during active treatmentCompleted todayPHQ-9 8, item 9 scored 0; no thoughts of suicide
SurveyPCL-5Baseline, then at each chronic-care visit during treatment; response judged after 8 to 12 weeksCompleted todayPCL-5 37 (41 at intake)
Medication safetySertraline: nausea, sleep, falls, bleeding, and sodium (SSRIs can lower sodium in older adults)Two weeks after starting and after each dose change; sodium at those pointsOrderedWell tolerated at 25 mg; raised to 50 mg today; sodium due in two to four weeks
ReferralTrauma-focused psychotherapy (cognitive processing therapy)Weekly, about twelve sessionsUp to dateThree of twelve sessions done, adapted with one-page summaries
ExaminationFall risk (Timed Up and Go, gait and balance), STEADIAt diagnosis, yearly, and after any fallUp to dateNo falls since intake
ReferralPhysical therapy for balance and strengthOnce, after a Timed Up and Go above 12 secondsReferredRebooked evaluation next week, with a reminder call
Self-managementTravel, money and home safetyAt diagnosis and each follow-upCompleted todayAddress card, shared phone location, company on unfamiliar routes and shared oversight of bills agreed
SurveyCare partner support and burden (Zarit Burden Interview, narrative)At diagnosis, then every 6 to 12 monthsCompleted todayZarit Burden Interview 14 (little to mild burden); helpline, caregiver class and GUIDE model explained for if dementia develops
Self-managementAdvance care planningAt diagnosis; revisit yearly and at changesDueHe wants to name a health care agent soon; booked for the annual wellness visit in seven weeks
ExaminationVascular risk factors (blood pressure, weight)Every visitCompleted todayBlood pressure 128/78 mmHg; weight 73.6 kg

Goal progress:

Guideline basis: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021); VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Depression/Bipolar/Mood Disorders monographs (2026); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); Guiding an Improved Dementia Experience (GUIDE) Model (2024)

Follow-up: Physical therapy evaluation next week. Annual wellness visit in seven weeks. Four-month review with PCL-5, PHQ-9 and sodium. Call the clinic or 988 at any time if thoughts of suicide arise. Next scheduled visit 2005-08-04: subsequent annual wellness visit. [S]